Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Krystexxa Market Through 2034?

In recent times, the krystexxa market has seen an XX (CAGR). Its size is projected to expand, moving from $XX million in 2024 to $XX million in 2025, indicating a compound annual growth rate (CAGR) of XX%. Such growth observed in the historical period can be linked to factors like a rising geriatric population, enhanced clinical studies, higher prevalence of chronic and refractory conditions, increased utilization of telemedicine in healthcare, and growing insurance coverage for biologic treatments.

The market size for krystexxa is predicted to witness a XX (CAGR) increase in the upcoming years, eventually reaching $XX million by 2029 with a compound annual growth rate (CAGR) of XX%. The expansion over the forecast period is mainly due to the rising instances of chronic diseases, increasing global population, the surge in demand for intravenous pegloticase, higher prevalence of gout, and increment in healthcare expenditures. The forecast period will also see major trends such as a shift towards subcutaneous delivery, incorporation of artificial intelligence in clinical trials, technological progress, innovative products, and advances in pegylation technology.

What Industry-Specific Factors Are Fueling the Growth of the Krystexxa Market?

The rise in gout disease cases is anticipated to stimulate the expansion of the Krystexxa market. Gout is a form of arthritis triggered by an accumulation of uric acid crystals in the joints, resulting in inflammation, discomfort, and swelling. The escalating prevalence of gout is linked to elements like improper diet habits, obesity, aging, certain drugs, genetic factors, chronic kidney disease, a lack of physical activity, and associated conditions such as hypertension and diabetes. Krystexxa (pegloticase) assists gout patients in managing their symptoms by reducing the uric acid levels in their blood, focusing particularly on chronic gout that is non-responsive to traditional treatments. This reduction in uric acid levels helps decrease the regularity and intensity of gout exacerbations, providing relief from the ailment’s painful symptoms. For instance, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in June 2024 that in 2022, gout contributed to 573 deaths in Australia, equating to 2.2 deaths per 100,000 individuals. This constituted 0.3% of the total deaths and represented 5.5% of all deaths from musculoskeletal disorders. Hence, the unfolding rise of gout is fuelling the growth of the Krystexxa market.

Get Your Free Sample of the Global Krystexxa Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20134&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Krystexxa Market?

Major companies operating in the krystexxa market include Amgen Inc.

Which Current Trends Are Having the Most Impact on the Krystexxa Market?

Focusing on combination therapy to boost effectiveness, lessen the emergence of anti-drug antibodies, and enhance patient outcomes in uncontrolled gout treatment, has emerged as a major trend in the krystexxa market. Combination therapy encompasses the simultaneous usage of two or more drugs or treatments to augment effectiveness and improve patient health. It is generally employed to tackle varying facets of a disease or ailment. For example, Horizon Therapeutics, a biotechnology corporation based in Ireland, was granted supplemental biologics license application (sBLA) to broaden the labeling encompassing Krystexxa (pegloticase) injection utilized in alliance with methotrexate, by the Food and Drug Administration, a federal agency in the US, in July 2022. In chronic gout patients unable to control their condition, a treatment combining Krystexxa (pegloticase) injection and methotrexate is used. The emergence of anti-drug antibodies is reduced by this combination therapy, which also boosts patient response.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/krystexxa-global-market-report

What Are the Major Categories and Their Growth Dynamics in the Krystexxa Market?

The krystexxa market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Lyophilized Powder), Ready-To-Use Solutions

2) By Indication: Treatment Of Chronic Gout, Management Of Hyperuricemia In Gout Patients, Treatment Of Refractory Gout

3) By Patient Demographics: Adult Patients, Elderly Patients, Patients With Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Specialty Clinics, Rheumatology Practices, Home Healthcare Providers

Which Regions Are Key Players in the Growth of the Krystexxa Market?

North America was the largest region in the krystexxa market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the krystexxa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Elements Shape the Definition of the Krystexxa Market?

Krystexxa (pegloticase) is a medication used to treat chronic gout in patients who are refractory to conventional therapies. It is an intravenous infusion that works by breaking down uric acid, thereby reducing uric acid levels in the body, which can help prevent gout attacks and related complications.

Browse Through More Similar Reports By The Business Research Company:

Gout Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Gouty Arthritis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

Bone And Joint Health Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-and-joint-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: